In this sense, it is well recognized that an appropriate cell-mediated immune response mediated by the activation of CD4+ and CD8+ T cells producing class I interferon, i.e., interferon (IFN)-α and IFN-β, and the activation of B cells producing neutralizing antibodies are associated with a favorable clinical outcome of COVID-19 (49–52). Here, CD8A is linked to COVID-19.